SuperSmart← Back to DiscoverDiscover
RESEARCH DRAFT

Research draft. Conclusions may change; review the sources and limitations before relying on them.

RESEARCH DRAFT · NOT A VERIFIED CONCLUSION

A 94.4% recall tally did not answer whether Tesla's remedy was adequate.

Tesla's recall report and NHTSA's separate remedy inquiry measure different things.

research_draftUpdated 2026-09-100 recorded actions
Conceptual generated illustration of documents and civic architectureCONCEPTUAL ILLUSTRATION

Monitor this connection

Sign in to your account to monitor updates
2Recorded evidence rows
0Investigation actions
3Review limitations
0Recorded answers

What this page shows

The second-quarter 2024 report for recall 23V838 lists 1,917,593 vehicles remedied out of a population of 2,031,220—about 94.4%. Separately, NHTSA opened recall query RQ24009 in April 2024 to examine the adequacy of the remedy, citing post-remedy events and other concerns. A high administrative completion rate does not, by itself, establish that a safety intervention works as intended. The more useful comparison is between installation or completion measures and exposure-adjusted outcomes after the remedy.

Recorded evidence

Tesla report filed with NHTSA
23V838 quarterly recall report2024 Q2; submitted July 2024
↗
NHTSA
Opening of recall query RQ240092024-04
↗

Limitations & review notes

  • Research draft. Conclusions may change; review the sources and limitations before relying on them.
  • Research draft: not independently verified and not actively monitored. This is a dated research lead, not a verified conclusion.
  • The report's remedied category has defined reporting inclusions; it is not an independent safety-effectiveness measurement. An investigation opening is not a final finding that the remedy failed. This draft does not assert the inquiry's current status.

Questions this connection opens

  1. What do comparable post-remedy crash rates and driver-engagement measures show after accounting for vehicle use and software versions?
Go deeper

Ask a follow-up question, compare another company, or review the supporting evidence.

Ask a follow-up